NEEDHAM, Mass., Dec. 29 /PRNewswire/ -- T Cell Diagnostics, Inc., a wholly owned subsidiary of T Cell Sciences, Inc. (Nasdaq: TCEL), today announced an exclusive U.S. distribution agreement relating to the sale and promotion of T Cell Diagnostics TRAx(R)CD4 and CD8 microtiter plate diagnostic kits with Diamedix Corpora
BUFFALO GROVE, Ill., Dec. 27 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced initiation of a Phase III clinical trial of nitazoxanide (NTZ) in Mexico , which is being supported by the Mexican licensee of NTZ. The objective is to test NTZ s safety and efficacy in treating AIDS patients infect
ABBOTT PARK, Ill., Dec. 27 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today it received clearance from the U.S. Food and Drug Administration to market clarithromycin (Biaxin) as a preventive agent for disseminated Mycobacterium avium complex ( MAC ). MAC, the most common systemic bacterial
SALT LAKE CITY, Dec. 27 /PRNewswire/ -- Utah Medical Products, Inc. (Nasdaq-NNM: UTMD) announces it has received U.S. Food & Drug Administration concurrence with its Cordguard II 510(k) submission. The elapsed time required for a substantive FDA review was less than 80 days. Sales of the device will begin immediate
BEAVERTON, Ore., Dec. 26 /PRNewswire/ -- Epitope, Inc. (AMEX: EPT) today announced that it has received notification from the U.S. Food and Drug Administration ( FDA ) that a premarket approval application (PMA) seeking permission to market its Western blot confirmatory test for use in HIV-1 testing with the company s
BOSTON, Dec. 22 /PRNewswire/ -- In the face of bitter cold weather and stinging federal budget cuts, shelters in Massachusetts and Rhode Island got some good news today: Citizens Energy Corporation announced a 20% increase in its annual Shelter Winter Assistance Program. Citizens Energy will spend $300,000 this winter,
NEW YORK, Dec. 21 /PRNewswire/ -- Sheffield Medical Technologies Inc. (AMEX: SHM) today announced it has entered into an agreement with Hemagen Diagnostics, Inc. to develop an ELISA assay to assess the progression of HIV in infected patients based on Sheffield s licensed HIV vaccine technology. The two companies will s
ABBOTT PARK, Ill., Dec. 21 /PRNewswire/ -- Abbott Laboratories has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking clearance for the use of the HIV protease inhibitor ritonavir to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune def
ABBOTT PARK, Ill., Dec. 21 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking clearance for the use of the HIV protease inhibitor ritonavir to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquir
WASHINGTON, Dec. 20 /PRNewswire/ -- The National Association of People with AIDS (NAPWA) has launched an education and prevention program to provide information about HIV-related cytomegalovirus ( CMV ) disease for health care providers and people living with HIV disease. NAPWA s CMV education and prevention progra
HUDDINGE, Sweden , Dec. 20 /PRNewswire/ -- Medivir AB announced today that it has entered into a research collaboration and licensing agreement with Abbott Laboratories (NYSE: ABT), of Abbott Park, Ill., U.S.A., to develop and commercialize anti-viral compounds. Under the terms of the agreement, Abbott will have wo
KIRKLAND, Wash., Dec. 15 /PRNewswire/ -- ProCyte Corporation (Nasdaq-NNM: PRCY) principal scientist Dr. Andrew Branca this week presented findings showing that the company s PC1323 compound inhibits the hepatitis B virus by preventing the release of the virus from infected cells. PC1323 is an isomer of ProCyte s BC
WARREN, N.J., Dec. 14 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) said it launched a US FDA-approved program for expanded access to its thalidomide drug Synovir(TM) for AIDS patients suffering from cachexia, a severe weight loss condition. Up to now, the drug has been available to the AIDS community only through
CAMBRIDGE, Mass., Dec. 14, /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that its partner Glaxo Wellcome (NYSE: GLX) has started Phase I/II clinical trials with VX-478 (141W94), a novel, orally administered protease inhibitor designed by Vertex for the treatment of HIV infection and
DUBLIN, Ireland , Dec. 13 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIBY) announced today that it has signed a three year contract with Warner-Lambert to be their exclusive supplier of pregnancy tests for the Over the Counter (OTC) market in the U.S.A. The pregnancy test will be sold by Warner-Lambert under the ep
CARLSBAD, Calif., Dec. 13 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received a notice of allowance from the European Patent Office and a patent from the Russian Patent Office regarding its core HIV technology. These patents, issued to inventors Jonas Salk, M.D. and Denni
MONTREAL and TORONTO, Dec. 12 /PRNewswire/ -- Glaxo Wellcome Inc. and BioChem Pharma Inc. announced today that the Drugs Directorate of the Health Protection Branch (HPB) of Health Canada has approved 3TC (R) (lamivudine) Tablets and Oral Solution under its pr
NEW YORK, Dec. 12 /PRNewswire/ -- North American Biologicals, Inc. (NABI) (Nasdaq: NBIO) today announced the expansion of its donor stimulation program for StaphGAM(TM), a product intended to prevent Staphylococcus aureus infections (Staph infections) in hospitalized patients. In the United States there are approxi
WASHINGTON, Dec. 12 /PRNewswire/ -- Future operations of the U.S. Preventive Services Task Force -- an independent advisory panel that today released its second edition of the Guide to Clinical Preventive Services -- will move to the Agency for Health Care Policy and Research to join the agency s other guideline activi
SAN DIEGO, Dec. 6 /PRNewswire/ -- Ligand Pharmaceuticals Inc. (Nasdaq: LGND) announced today Steven D. Reich, M.D., formerly Senior Vice President of Parexel International Corporation, a leading clinical contract research organization (CRO), has joined Ligand as Senior Vice President, Clinical Research. The addition of
FORT LAUDERDALE, Fla., Dec. 11 /PRNewswire/ -- Determined to surpass contributions from last year s special holiday soft drink sales promotion which benefited two national charities, National Beverage Corp. (Nasdaq: POPS) chairman, Nick A. Caporella, announced today the launching of this year s program for those charit
ALEXANDRIA, Va., Dec. 11 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI CELIW) today announced the start of a clinical study with the HGP-30 HIV immunogen. The study is being conducted at the clinic of AIDS RESEARCH Alliance, a non-profit AIDS research organization located in West Hollywood, California. The phase I
HARRISBURG, Pa., Dec. 7 /PRNewswire/ -- Pennsylvania Gov. Tom Ridge today canceled Monday s noon Christmas Tree Lighting ceremony, saying he would not subject hundreds of young children to the harsh tactics of the protest group ACT UP. ACT UP has announced that busloads of protesters will arrive at the Capitol Monday m
WASHINGTON, Dec. 7 /PRNewswire/ -- The Food and Drug Administration today approved the first protease inhibitor, a new class of therapy for the treatment of advanced HIV infection. Saquinavir , the new drug, received approval for use in combination with older nucleoside analogue medications only three months after the
NUTLEY, N.J., Dec. 7 /PRNewswire/ -- To respond to the immediate needs of people with AIDS, Roche Laboratories announced today that Invirase (TM) ( saquinavir mesylate) capsules, the first in a new class of drugs called HIV
SEATTLE, Dec. 7 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN) has named Bruce H. Devens, Ph.D. to the position of director of immunology. He will have responsibility for directing Targeted Genetics immunology department, and will play a critical role in directing the company s cytotoxic T lymphocyte (CTL
MARNES LA COQUETTE, France , Dec. 7 /PRNewswire/ -- The following was issued by the Albert B. Sabin Vaccine Foundation: It is time to recognize and celebrate the fierce determination of Albert B. Sabin and Jonas Salk, states H.R. Shepherd, C.E.O. of the Albert B. Sabin Foundation. Although they were rivals during thei
ACADEMIC MEDICAL CENTER, UNIVERSITY OF AMSTERDAM, The Netherlands , Dec. 6 /PRNewswire/ -- The Academic Medical Center of University of Amsterdam today released the following: Pronounced antiviral activity and immunologic benefits were maintained in HIV infected individuals after 32 weeks of treatment with the experime
NEW YORK, Dec. 6 /PRNewswire/ -- Monotherapy with the experimental protease inhibitor ritonavir (formerly known as ABT-538) significantly reduced plasma viremia and elevated CD4 lymphocyte counts in HIV-infected people, according to a new multi-center study published in the Dec. 7 issue of The New England Journal of Me
TOPIC: Debra Fraser-Howze, appointed by President Clinton, is attending the conference as a Presidential Advisory Council Member on AIDS and HIV with the primary purpose of bringing the nation s attention to what is labeled as the new epidemic. AIDS is the number one cause of death for Black women in their childbearing
PALO ALTO, Calif., Dec. 6 /PRNewswire/ -- SyStemix, Inc. (Nasdaq: STMX) and its collaborators presented data at the American Society of Hematology (ASH) meeting which addressed the broad utility of its patented CD34+Thy+Lin- hematopoietic stem cells (HSCs). Interim results were presented from its Phase I/II trial, usin
ST. PAUL, Minn., Dec. 5 /PRNewswire/ -- From the Independent Television Service comes the following announcement: On the heels of World AIDS Day, President Clinton has invited many of the nation s key experts and spokespersons involved with the HIV/AIDS epidemic to join the Presidential Advisory Council on HIV/AIDS at
ABBOTT PARK, Ill., Dec. 4 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) today announced details of an expanded access treatment program that will make its protease inhibitor, ritonavir (formerly known as ABT-538), available in January via a lottery to approximately 2,000 patients worldwide with advanced AIDS.
PHILADELPHIA, Dec. 4 /PRNewswire/ -- The American Friends Service Committee released the following: In the shadow of International World AIDS Day, a national gay and lesbian youth project sponsored by the American Friends Service Committee (AFSC) criticized scheduled Congressional hearings set for this week. The AFSC-s
The following advisory was released today by Kaiser Permanente: If I thought Kaiser Permanente wasn t taking care of HIV/AIDS patients with zeal I wouldn t be a physician here, says George Matula, MD, Co-Director of the HIV Research Unit at Kaiser Permanente in San Francisco. Our HIV/AIDS programs are world class.
WARREN, N.J. Dec. 1 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) was issued US Patent No. 5,463,063 for a scaleable process to make high purity thalidomide, a drug the company is currently clinically testing for a number of different therapeutic indications. The patent covers a new method to manufacture Celgene s
DETROIT / December 1 /PRNewswire/ At a special ceremony to commemorate World AIDS Day on December 1, 1995, Steppin Out will present $140,000 in grant awards to 13 agencies serving people living with AIDS in southeastern Michigan. The presentation will take place at St. Dominic s Catholic Church, 1419 W. Warren, Detroit
OAKLAND, Calif., Dec. 1 /PRNewswire/ -- Since 1981 Kaiser Permanente physicians have treated AIDS patients. At that time, most physicians and health care organizations didn t or wouldn t recognize the epidemic or treat those with the disease. Kaiser Permanente physicians did. Today, Kaiser Permanente continues to demon
WASHINGTON, D.C. and OAKLAND, Calif., Dec. 1 /PRNewswire/ -- Secrets, a professionally performed play for adolescents and teens (and their parents), presents a powerful and preventive AIDS message for World AIDS Day, December 1. The health education play, a community service of Kaiser Permanente, will be performed for
DETROIT, Nov. 28 /PRNewswire/ -- The Southeastern Michigan Chapter of the American Red Cross is offering free pre-marital health counseling for the first 12 couples to arrive for a class to be held December 1 -- World AIDS Day. By State law every couple has to take this training before they marry. Because much of the s
ATLANTA, Nov. 30 /PRNewswire/ -- Cumulative number of AIDS cases in Georgia since 1981, as reported to the Department of Human Resources, Division of Public Health, Epidemiology and Prevention Branch, AIDS Surveillance. Reported as of Oct. 31, 1995 Cases Deaths Adults 14,008 Adults 7,970 Childr
MUNCIE, Ind., Nov. 30 /PRNewswire/ -- AIDS can be controlled, contrary to a feeling among many that it can t, says Lorraine Jones, a recognized HIV/AIDS advisor to national, state and local groups. She has a program for doing just that. Starting with local health departments and battling AIDS with programs developed at
SEATTLE, Nov. 30 /PRNewswire/ -- A new molecule discovered and cloned by Immunex Corporation (Nasdaq: IMNX) may provide the basis for a significant advance in immunology. The molecule, Flt3 ligand (Flt3-L), has been shown to promote the growth of dendritic cells, a formerly elusive type of cell which plays a key role i
FORT LAUDERDALE, Fla., Nov. 30 /PRNewswire/ -- The Blockbuster Music store at 6460 S. Dixie Hwy., South Miami, will host an in-store appearance of The Rembrandts on Saturday, Dec. 2, as part of CounterAid, the national week-long fundraising effort coordinated by LIFEbeat, a not- for-profit AIDS resource and awareness o
GRAND RAPIDS, Mich., Nov. 30 /PRNewswire/ -- The formation of an A.I.D.S. support group network called He Intends Victory (H.I.V.) Outreach is being announced in observance of World AIDS Day 1995. The organization has the goal of helping the Michigan Christian community by providing Bible-based support to those who are
NEW YORK, Nov. 30 /PRNewswire/ -- In conjunction with World AIDS Day and A Day Without Art (Dec. 1), ENTERTAINMENT WEEKLY publishes its fifth annual tribute to members of the entertainment industry lost to AIDS in the past year. In this year s Faces of AIDS spread, the magazine presents 120 photographs with the hope th
BOCA RATON, Fla. and ROCKVILLE, Md., Nov. 30 /PRNewswire/ -- North American Biologicals, Inc. (Nasdaq: NBIO) (NABI) and Univax Biologics, Inc. (Nasdaq: UNVX) announced today that they have completed the merger of the two companies. At separate meetings held November 29, the stockholders of each company approved the mer
SEATTLE, Nov. 29 /PRNewswire/ -- PATH -- The Program for Appropriate Technology in Health -- Seattle, Wash., has developed RiskAdvisor, an easy-to-use interactive software program that allows individuals to assess their personal risk of HIV infection based on their present patterns of behavior. The program then helps u
MINNEAPOLIS, Nov. 29 /PRNewswire/ -- Organetics, Ltd., is a privately held, Minneapolis, Minn. based medical device corporation that was formed in 1989. Organetics developed and patented the Virolyzer(TM) PS-1 system, an integrated blood perfusion system that performs various extracorporeal treatment procedures. The co
The Joint United Nations Programme on HIV/AIDS ( UNAIDS ) and the Department of Public Information (DPI) will co-sponsor a panel discussion at Headquarters on December 1 in observance of World AIDS Day. Following the discussion, Metropolitan Opera artists will give a special concert organized by the Ambassadors of Oper
ATLANTA, Nov. 29 /PRNewswire/ -- This year World AIDS Day celebrations will highlight the ways people in local communities are getting together to take responsibility for stopping the spread of the disease, and helping people who are living with HIV/AIDS, according to Kathleen E. Toomey, M.D., M.P.H., director of the G
SEATTLE, Nov. 28 /PRNewswire/ -- Bastyr University s Center for Alternative Medicine Research in HIV/AIDS is recruiting people who are HIV-positive to participate in the first nationwide study of alternative medicine and HIV/AIDS. Bastyr University is the only regionally accredited multidisciplinary natural medicine un
NEW YORK, Nov. 28 /PRNewswire/ -- What do Donna Summer, computer product vendors and a big, fat magazine have in common? They are all part of a first-of-its-kind awards ceremony that not only celebrated computer industry winners but raised nearly a quarter of a million dollars for two worthy causes helping children in
THE WOODLANDS, Texas, Nov. 28 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX) today announced that the European Patent Office has issued a key patent covering technology for producing Nystatin(LF), the Company s liposomal product in clinical development for the treatment of serious fungal infections. The pa
FOSTER CITY, Calif., Nov. 28 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) announced today that the waiting period under the Hart-Scott-Rodino Act related to the company s collaboration with Hoechst Marion Roussel (HMR) for its AIDS gene therapy program, has expired without action by the Federal Trade Commission or
BOSTON, Nov. 28 /PRNewswire/ -- The New England Corporate Consortium for AIDS Education -- in commemoration of World AIDS Day -- will hold its annual business breakfast on Friday, December 1 at the Museum of Fine Arts in Boston. The theme is Shared Rights and Shared Responsibility, focusing on creating supportive work
NEW YORK, Nov. 28 /PRNewswire/ -- On Wednesday, December 6, from 7:30 to 11 p.m., the Children s Hope Foundation (CHF), which supports over 3,200 New York City area children with HIV/AIDS, will host a truly unique holiday benefit at the Pier 59 Studio LP fashion photography studio at Chelsea Piers. Hosted by John Barro
The following was released by the American Red Cross Southeastern Michigan Chapter. All statistics provided by the Michigan Department of Public Health at October 1995: * The annual rate of AIDS-related deaths in Michigan continues to rise. * On World AIDS Day (December 1), sponsored by the World Health Organization, 1
On Thursday, November 30, the U.S. Department of Health and Human Services will release a new series of public service announcements (PSAs) urging young Americans to take personal responsibility for protecting themselves from HIV infection. HHS Secretary Donna E. Shalala will cite data that substantiate both the increa
WHO: The American Association for World Health and Metro TeenAIDS in association with the World AIDS Day 1995 Advisory Committee are sponsoring the World AIDS Day 1995 National Program focusing on the 1995 theme: Shared Rights, Shared Responsibilities WHAT: The shared responsibility of our nation, communities, families
SPRINGFIELD, Va., Nov. 28 /PRNewswire/ -- The genetic variability of HIV has surpassed anything we have imagined in the early 1980 s. Already some 14 million people have been infected, and the World Health Organization now estimates that by the year 2000 some 30-40 million people, including millions of children, will b
CHICAGO, Nov. 28 /PRNewswire/ -- Wisconsin Pharmacal (AMEX: FHC) today announced that it has signed a definitive agreement to purchase 100 percent of the outstanding shares of Chartex Resources Limited of London, U.K. Chartex owns the worldwide rights to the female condom, which is sold in the United States by
HOPKINTON, Mass., Nov. 27 /PRNewswire/ -- Seragen, Inc. (Nasdaq: SRGN). Seragen, Inc. announced today the formation of Seragen Biopharmaceuticals Ltd., a privately held Canadian operating company to be located in Montreal. In a private financing, the new company raised $13.5 million (CDN) from a group of six Canadian i
BURBANK, Calif., Nov. 24 /PRNewswire/ -- Four years ago today, on November 24, 1991, Queen lead singer Freddie Mercury passed away due to AIDS-related causes. Mourned by millions around the world, Mercury was undoubtedly one of the greatest legends the rock world has ever known. Now Mercury s presence is once more bein
THE WOODLANDS, Texas, Nov. 22 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX), which was recently formed by the merger of Argus Pharmaceuticals, Inc., with Triplex Pharmaceutical Corporation and Oncologix, Inc., today reported a net loss for the third quarter ended September 30, 1995 of $9.8 million, or $0.
PR Newswire - (Nov 21): LOCATION: Entrance Area of the Huntington Shorecliffs Mobile Home Park, 20701 Beach Boulevard Huntington Beach, CA 92648 WHEN: Tuesday, November 21, 1995 TIME: 10 a.m. As most families are preparing for Thanksgiving dinner this week, one family is preparing for a completely different event. A f
WASHINGTON, Nov. 20 /PRNewswire/ -- The Food and Drug Administration today announced its accelerated approval for the drug lamivudine, or 3TC , for use in combination with AZT (zidovudine) in treating AIDS and HIV infection.
RESEARCH TRIANGLE PARK, N.C., Nov. 20 /PRNewswire/ -- The anti-HIV drug Epivir (TM) brand lamivudine, formerly known as 3TC (TM), was released for marketing late on Friday, November 17, by the Food and Drug Administration. Epivir is indicated for use in combination wi
RESEARCH TRIANGLE PARK, N.C., Nov. 20 /PRNewswire/ -- The anti-HIV drug Epivir (TM) brand lamivudine, formerly known as 3TC (TM), was released for marketing late on Friday, November 17, by the Food and Drug Administration. Epivir is indicated for use in combination wi
TARRYTOWN, N.Y., Nov. 17 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. today announced the publication of a scientific paper on PRO 542 in the November issue of Journal of Virology (vol. 69, no. 11). PRO 542 is being developed as an immunotherapy to treat or prevent human immunodeficiency virus (HIV) infection, the c
WARREN, N.J., Nov. 17 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) said net losses for the third quarter ended September 30 were $2.4 million, or 30 cents a share, versus $2.1 million, or 27 cents a share, a year ago on revenue of $412,000 compared to $758,000. The decline in revenue was due principally to lower
NORWELL, Mass., Nov. 16 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has granted Serono Laboratories, Inc. priority review status for Serostim (TM) the company s mammalian cell-derived recombinant human growth hormone (r-hGH(m), for the treatment of AIDS wasting in adults.
FOSTER CITY, Calif.--(BW HealthWire)--Nov. 16, 1995-- Gilead Sciences , Inc. (NASDAQ: GILD) and a team of collaborating researchers from the University of Washington and the National Institutes of Health (NIH) reported that Gilead s PMPA compound provided the first complete protection against the development of simian
ALEXANDRIA, Va., Nov. 15 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq-NNM: CELI, CELIW) announced that the State of California Food and Drug Branch has given clearance to start human testing of CEL-SCI s HIV immunogen, HGP-30 in HIV infected individuals. The study is expected to start before year-end in West Hollywood,
ITHACA, N.Y., Nov. 15 /PRNewswire/ -- Paracelsian, Inc., (Nasdaq: PRLN) today announced they are negotiating a letter of intent for a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) and the National Institute of Child Health and Human Development (NICHD) at the National I
TORONTO, Nov. 15 /CNW-PRN/ - It has been estimated by the World Health Organization that by the year 2000, there will be 10 million children infected with the AIDS virus. The few organizations which are striving to give these children the necessities of life need our support. With enthusiastic support from the marketpl
NEW YORK, Nov. 14 /PRNewswire/ -- Looking for gifts in good taste this holiday season? Distinctive delectables and more -- all benefiting non-profit organizations serving the chronically ill -- are available at Stadtlanders Pharmacy Wellness Center located at 126 Eighth Avenue, near 16th Street in the Chelsea area of M
CARLSBAD, Calif., Nov. 14 /PRNewswire/ -- Isis Pharmaceuticals , Inc. (Nasdaq: ISIP) announced it has received a notice of allowance for a patent on ISIS 5320, a compound in preclinical development that has been shown in vitro and in vivo to be a potent and specific inhibitor of HIV, the virus that causes AIDS. ISI
NEW YORK, Nov. 10 /PRNewswire/ -- Sheffield Medical Technologies Inc. (AMEX: SHM) today announced its operating results for the third quarter ended September 30, 1995. For the quarter, the Company reported a net loss of $2.1 million, or $0.24 per share, compared to $2.1 million, or $0.30 per share, in the third quarter
VIRGINIA BEACH, Va., Nov. 10 /PRNewswire/ -- Following three years of development and extensive validation, LifeNet has now implemented a revolutionary new bone processing and cleaning technology which may help to virtually eliminate the possibility of disease transmission through the implantation of processed human bo
ATLANTA, Nov. 8 /PRNewswire/ -- The following was issued today by CDB Healthcare for Pfizer Inc.: Chlamydia trachomatis continues to pose significant health risks for women, surpassing gonorrhea as the number one bacterial sexually transmitted disease (STD) in the United States with four mil
STAMFORD, Conn., Nov. 8 /PRNewswire/ -- VIMRx Pharmaceuticals Inc. (Nasdaq Small Cap: VMRX (common stock), VMRXW (warrants)) announced today that it has received approval from the Ministry of Public Health of Thailand to conduct clinical trials with VIMRxyn for the treatment of AIDS. VIMRxyn is a synthetic version of h
ATLANTA, Nov. 8 /PRNewswire/ -- A.D.A.M. Software, Inc. today announced the availability of Life s Greatest Mysteries, an interactive CD-ROM journey exploring life s most intriguing questions and providing the answers everybody wants to know. The program is hosted by the ever inquisitive Bob Winkle. This slightly eccen
ITHACA, N.Y., Nov. 7 /PRNewswire/ -- Paracelsian, Inc. (Nasdaq: PRLN), announced today that it had filed a continuation in part (CIP) on its U.S. patent for PN355 (Application 08/349,999) describing further experiments involving the inhibition of the HIV-1 virus (the virus that causes AIDS), as well as details concerni
NUTLEY, N.J., Nov. 7 /PRNewswire/ -- The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration ( FDA ) today recommended approval for Invirase (TM) ( saquinavir ) -- the first compound in a new class of AIDS therapi
LOS ANGELES, Nov. 6 /PRNewswire/ -- David Hyde Pierce, Celebrity Chairman for CARING FOR BABIES WITH AIDS (CBA) 5th Annual Fundraising Stroll-A-Thon Sunday, November 12, 1995 at Roxbury Park in Beverly Hills, California, will be joined by deeply concerned celebrities and an anticipated 2,500 supportive Los Angeles citi
PRNewswire -- Nov. 6/ 12:30 EST WHAT: On November 8, 1995, during an interactive satellite symposium broadcast nationally to health care providers in STD and family planning clinics, the Centers for Disease Control and Prevention, together with the American Social Health Association and the National Association of Nurs
NEW HAVEN, Conn., Nov. 6 /PRNewswire/ -- Following today s announcement that the Food and Drug Administration ( FDA ) Antiviral Drugs Advisory Committee recommended approval of the anti-HIV and -HBV drug known as 3-TC, John A. Spears, the President and C.E.O. of the New Haven, Connecticut-based OncoRx, Inc. (Nasdaq: OC
LANSING, Mich., Nov. 2 /PRNewswire/ -- Attorney General Frank J. Kelley announced today that he has filed lawsuits against two organizations and two professional fund raisers for illegal charitable solicitations in Michigan. Kelley is seeking court orders to force the organizations to stop further solicitation in Michi
NEW YORK, Nov. 2 /PRNewswire/ -- In testimony today before a Congressional Subcommittee, Mark Philip, Ph.D., Chief Executive Officer of Immuno-U.S., Inc., outlined the comprehensive program the company has developed and implemented to further improve the margin of safety in the collection of plasma and the manufacture
SEATTLE, Nov. 2 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN) today reported a net loss of $2,220,000, or $0.19 per share for the third quarter ended September 30, 1995, down from a loss of $2,225,000, or $0.25 per share, for the same period in 1994. The decrease in loss per share was related to addition
DUBLIN, Ireland , Nov. 2 /PRNewswire/ -- Trinity Biotech (Nasdaq: TRIBY) announced that the Company had raised a further $3.0 million from European Institutional Investors. The Placement completes the Offering to institutional investors which Trinity initiated in July of this year with total proceeds of $6 million.
WASHINGTON, Nov. 2 /PRNewswire/ -- A five-year program to teach community college students the essentials of HIV prevention and to involve them in programs to protect their communities against the infection is being launched this month by the American Association of Community Colleges (AACC) under a cooperative agreeme
BELTSVILLE, Md., Nov. 1 /PRNewswire/ -- Thalidomide is unequivocally safe and effective for the treatment of AIDS-associated oral canker sores, according to a mid-trial review of data from a controlled nationwide clinical trial. The Phase II/III clinical trial, co-sponsored by the Division of AIDS (DAIDS), National Ins
SEATTLE, Nov. 1 /PRNewswire/ -- The nation s blood banks no longer have to rely solely on screening blood for a potentially fatal virus that affects certain marrow and organ transplant patients, according to a new study by Hutchinson Center scientists. The results of the landmark study, which were published in the Nov.
CHAPEL HILL, N.C., Nov. 1 /PRNewswire/ -- Triangle Pharmaceuticals today announced that it has completed a $4 million, first round financing to advance its programs to develop novel therapeutics for serious viral diseases and cancer. The recently established company, headed by Dr. David Barry, former President of The W
THE WOODLANDS, Texas, Nov. 1 /PRNewswire/ -- Researchers at Aronex Pharmaceuticals (Nasdaq: ARNX), the Katholieke Universiteit Leuven, the National Cancer Institute, the University of California at San Francisco and the Southern Research Institute today reported laboratory results indicating that a new anti-HIV drug ca
NUTLEY, N.J., Oct. 31 /PRNewswire/ -- Hoffmann-La Roche announced today that it has received marketing clearance from the U.S. Food and Drug Administration ( FDA ) for the first preventive treatment for HIV-related cytomegalovirus ( CMV ) disease.
In Investigational New Drug Shows Promising Results, moved Oct. 25, the contact should read Please contact Omega Pharmaceutical at 205-969-3003 for information on enrolling in the upcoming U.S. Trial. Media Contact: Nicki Gibbs, 612-798-7209, or 800-999-4859 rather than Nicki Gibbs of Omega Pharmaceutical, 205-969-3003
ANN ARBOR, Mich., and COLLEGEVILLE, Pa., Oct. 26 /PRNewswire/ -- AASTROM Biosciences, Inc. and Rhone-Poulenc Rorer Inc. (NYSE: RPR) today announced a collaboration to develop the automated AASTROM(TM) Cell Production System (CPS) for cell and gene therapies involving lymphoid blood cells, a strategic focus within RPR G
MINNEAPOLIS, Oct. 25 /PRNewswire/ -- Omega Pharmaceutical, Inc. today announced that it has recently completed a three-year phase II clinical trail on an Investigational new Drug called PCM-4. Results were very positive, and indicate that PCM-4 enhances the quality and may lengthen the life of AIDS patients suffering f
The Centers for Disease Control and Prevention (CDC), in partnership with top leaders from the business community, will hold a press conference Friday, October 27, 1995, in New York City, to announce a national workplace-related public service campaign that urges businesses to make AIDS their business. The new campaign
NEW YORK, Oct. 25 /PRNewswire/ -- People who suffer from immune thrombocytopenic purpura (ITP) -- a serious bleeding disorder triggered by a low blood platelet count -- and the medical professionals who treat them, will participate in the nation s first ITP Family Support Day, Saturday, January 20, 1996. ITP Family Sup
BUFFALO GROVE, Ill., Oct. 25 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced higher revenues for the three and nine months ended September 30, 1995. Quarterly Earnings Down Due to Unusual Items The sales increases resulted from our focus on Marinol(R), which stimulates appetite in AIDS patie
Unsung heroes and nationally known leaders are among the recipients of the 1995 Jessie Bernard Wise Women Awards to be presented on Thursday, October 26, 1995 at the Omni Shoreham Hotel, in Washington, D.C. from 6:00 - 9:00 p.m. The Center for Women Policy Studies established the Jessie Bernard Wise Women Awards in 198
MIAMI BEACH, Fla., Oct. 25 /PRNewswire/ -- The public s patriotic response to calls for blood donations during a military emergency does not compromise the safety of the blood supply, according to research presented at the 46th Annual Meeting of the American Association of Blood Banks (AABB). The study, conducted by Ba
CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported financial results today for the three months and nine months ended September 30, 1995. Revenues for the third quarter were $3,493,000 derived from collaborative research and development and interest income, as compared
HAYWARD, Calif.--(BUSINESS WIRE)--Oct. 25, 1995--RiboGene, Inc. has been awarded a Small Business Innovation Research (SBIR) phase II grant to develop novel drugs for fungal infections. The grant, worth up to $750,000 over two years, will support the company s proprietary approach to the discovery and development of an
WASHINGTON, Oct. 24 /PRNewswire/ -- Results from a placebo- controlled study supported by the National Institute of Mental Health (NIMH) provide no evidence that Peptide T has an effect on neuropsychological performance in HIV seropositive individuals with cognitive impairment. Initial analyses of the primary efficacy
ITHACA, N.Y., Oct. 20 /PRNewswire/ -- Paracelsian, Inc. today issued the following: A proprietary screening technology created by Paracelsian, Inc. (Nasdaq: PRLN) has identified 32 extracts of Traditional Chinese Medicines (TCMs) that hold significant potential for preventing sexual transmission of AIDS. Tests at Frede
FOSTER CITY, Calif., Oct. 19 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) reported revenues of $4.1 million for the third quarter ended September 30, 1995 compared with $1.7 million during the third quarter a year ago. The increase is primarily related to initial research and development funding of the company s g
BOSTON, Oct. 18 /PRNewswire/ -- Boston s Beth Israel Hospital and Bowdoin Street Health Center of Dorchester have signed an agreement to share responsibility for the management and operation of the 23-year-old community health center, long considered an essential health care resource for many inner-city residents. This
WASHINGTON, Oct. 13 /PRNewswire/ -- The nation s second largest AIDS organization, and the preeminent national organization that deals with AIDS as a business and workplace issue, will merge on January 1, 1996, it was announced today. This is the first time two major national AIDS organizations have merged. The Boards
PHILADELPHIA, Oct. 13 /PRNewswire/ -- Investigators at The Wistar Institute, an internationally renowned biomedical research institute based in West Philadelphia, said they have received notice from the U.S. Patent and Trademark Office of allowance for a patent covering Interleukin-12 (or IL-12), Natural Killer Stimula
WARREN, N.J., Oct. 13 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) said the U.S. FDA approved a request to recover costs of providing its experimental thalidomide drug (Synovir(TM)) to AIDS patients eligible for entry into the company s expanded access trial for cachexia, a severe wasting condition.
RESEARCH TRIANGLE PARK, N.C., Oct. 12 /PRNewswire/ -- A new therapy for shingles (herpes zoster), a painful and potentially debilitating disease that affects hundreds of thousands of older Americans each year, has been released for marketing by the Food & Drug Administration. Valtrex(R) brand valacyclovir HC1, indi
MIAMI, Oct. 11 /PRNewswire/ -- A group of nationally recognized health care consultants, including a former senior advisor on AIDS policy to President Clinton, have formed a new company, LifeWay, Inc. to provide comprehensive health care services for patients with chronic diseases, including HIV/AIDS, cardiology and as
KANSAS CITY, Mo., Oct. 10 /PRNewswire/ -- Hoechst Marion Roussel, the global pharmaceutical division of Hoechst AG, today announced the signing of a gene therapy collaboration with Cell Genesys, Inc., a biotechnology company based in Foster City, CA. The initial focus of the collaboration is research and development of
FOSTER CITY, Calif., Oct. 10 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) announced today a collaboration with Hoechst Marion Roussel (HMR) for the worldwide development and commercialization of Cell Genesys gene therapy program for AIDS. The agreement provides for committed payments of more than $50 million durin
SAN FRANCISCO, Oct. 9 /PRNewswire/ -- Project Open Hand will commemorate its ten years of delivering hot meals and groceries to people with symptomatic HIV and AIDS on Thursday, October 19. Ten Years and Still Cookin will mark the start of the second decade of service for this remarkable organization. Project Open Hand
NEW YORK, Oct. 5 /PRNewswire/ -- Today s New York City Council resolution calling for federal and state legislation that would require testing of newborns for HIV and the disclosure of the results to parents is a direct challenge to a U.S. House-Senate committee soon to determine federal AIDS policy, says the Independe
PHILADELPHIA, Oct. 5 /PRNewswire/ -- Twelve area church congregations and Philadelphia area residents living with HIV/AIDS will gather Sunday evening, October 8th, in a vigil to pray for a resolution to the crisis facing the residents of Betak, the state s only AIDS nursing home, which is scheduled to close because of
EDMONDS, Wash., Oct. 5 /PRNewswire/ -- Receptagen Ltd. (OTC Bulletin Board: RCEPF; Toronto: RCG) today announced it has signed a letter of intent with a major Japanese drug manufacturer to jointly develop drugs that inhibit apoptosis, or programmed cell death, with application to AIDS, heart disease, stroke and neurode
THE WOODLANDS, Texas, Oct. 5 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX) today announced the initiation of a Phase I clinical trial with AR177, a novel compound with a unique mechanism of action for the treatment of AIDS and HIV infection. The Phase I study will be conducted in HIV-positive patients und
DETROIT, Oct. 5 /PRNewswire/ -- Michigan women are not receiving comprehensive, well-integrated health care according to The Fragmented Woman: Health Issues for Michigan Women, a report released today by the Michigan Women s Foundation. The report calls upon Michigan policy makers, funding sources, and health care prov
PHILADELPHIA, Oct. 4 /PRNewswire/ -- The Philadelphia AIDS Consortium is now building a pool of volunteers willing to serve as review panelists for funding applications. In particular, the Consortium is looking for persons living with HIV disease, people familiar with HIV/AIDS issues, and people familiar and experience
TARRYTOWN, N.Y., Oct. 4 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. today announced that, in conjunction with the Southwest Foundation for Biomedical Research (San Antonio, TX) and the University of Oklahoma (Oklahoma City, OK), it has been awarded a three year, $1.9 million contract from the U.S. Department of Def
FOSTER CITY, Calif., Oct. 3 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) announced today that patient enrollment has recently begun for the Phase II portion of an initial clinical trial of anti-HIV T cell gene therapy for AIDS, which is being conducted at the National Institute of Allergy and Infectious Diseases.
LOS ANGELES, Oct. 2 /PRNewswire/ -- While Jeff Fylling is competing in the Ironman Triathlon, the real winners will be patients at the City of Hope National Medical Center and Backman Research Institute. On October 7, Fylling will be one of 1,500 athletes from more than 50 countries competing in the Gatorade Ironman Tr
THE WOODLANDS, Texas, Oct. 2 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX) announced today that the National Institute of Allergy and Infectious Diseases has awarded the Company four Phase I Small Business Innovation Research ( SBIR ) grants totaling $400,000. Funds are slated for the development of AR177
SACRAMENTO, Calif., Sept. 29 /PRNewswire/ -- The California Department of Corrections today announced the results of two unique studies: A systemwide tuberculosis (TB) screening of inmates and employees; and A seroprevalence study of 5,000 incoming inmates for HIV and hepatitis. We are adding an entirely new chapt
WASHINGTON, Sept. 29 /PRNewswire/ -- They are women and men. They are Democrats and Republicans. They work in state capitols and the nation s Capitol. And they are united in their commitment to improving women s health. On Monday, October 2, seven legislators will be honored for their commitment by WiLL, the Women Legi
SAN FRANCISCO, Sept. 28 /PRNewswire/ -- Ligand Pharmaceuticals Inc. (Nasdaq: LGND) today announced interim results of controlled Phase I/IIb human clinical trials indicating that Targretin(TM) Topical (LGD1069) induced a partial or complete response in one or more treated lesions in 52 percent of 23 patients with AIDS-
SAN DIEGO, Sept. 28 /PRNewswire/ -- Allergan Ligand Retinoid Therapeutics, Inc. (Nasdaq: ALRIZ) today announced interim results of controlled Phase I/IIb human clinical trials indicating that ALRT1057 Topical (9-cis-retinoic acid) induced a partial or complete response in one or more treated lesions in 65 percent of 20
FOSTER CITY, Calif., Sept. 27 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) announced today that the company has entered into a collaborative agreement with the Ludwig Institute for Cancer Research and the Sloan-Kettering Institute for Cancer Research of New York which provides a portfolio of antibody reagents for
NEW YORK, Sept. 27 /PRNewswire/ -- Positive Music today announced the opening concert of its 1995-1996 Center Series, to take place on Monday, October 16, 1995, at 8:00 p.m. at the Lesbian and Gay Community Services Center at 208 West 13th Street in Manhattan. Admission is free. On the program are Elliot Carter s Ench
BELTSVILLE, Md., Sept. 27 /PRNewswire/ -- Andrulis Pharmaceuticals Corporation, a privately held drug development firm, today announced that the FDA has authorized and it has commenced a Phase I/II clinical trial of thalidomide against multiple sclerosis (MS). Andrulis said its investigators at UCLA will attempt to det
LOS ANGELES, Sept. 26 /PRNewswire/ -- Celebrated contemporary artist Laddie John Dill will design a limited edition of holiday cards for the Weingart Center Association this year. Proceeds will support the many innovative programs at the Weingart Center, the nation s most comprehensive transitional housing, health and
WASHINGTON, Sept. 25 /PRNewswire/ -- The preview performance of Mano-A-Mano, the opening production of GALA Hispanic Theatre s 20th Anniversary Season, will benefit Salud, Inc. s health programs in the Latino communities of the Washington Metropolitan Area. This special performance will be presented on Wednesday, Octob
LA JOLLA, Calif., Sept. 22 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., (Nasdaq-NNM: AGPH) today announced that it has received from the United States Patent and Trademark Office (PTO) a notice of allowance in the patent application covering the chemical composition of the anti-HIV drug VIRACEPT(TM) (AG1343).
CARLSBAD, Calif., Sept. 18 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has entered into an agreement with Trinity Medical Group, Co., Ltd. of Thailand for the development of the Salk Immunogen in Thailand and certain other countries in Asia. Trinity Medical Group is a division
PRINCETON, N.J., Sept. 14 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) issued the following statement: Bristol-Myers Squibb is pleased that the results of the AIDS Clinical Trials Group (ACTG) 175 study, announced earlier today by the NIH, demonstrate that antiretroviral therapy is of benefit to asymptomatic patien
CARLSBAD, Calif., Sept. 5 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received an official notice of allowance from the Japanese Patent Office regarding its core HIV therapy technology. This patent, issued to inventors Jonas Salk, M.D. and Dennis J. Carlo Ph.D., has been l
This information is designed to support, not replace, the relationship that exists between you and your doctor.